Purinergic signalling in graft-versus-host disease

Area of Science:

• Immunology
• Cell Biology
• Pharmacology

Background:

• Allogeneic hematopoietic stem cell transplantation (HSCT) is a critical treatment for hematologic malignancies.
• Graft-versus-host disease (GVHD) remains a major life-threatening complication following HSCT.
• The role of purinergic signaling in human GVHD is not fully understood.

Purpose of the Study:

• To investigate the role of purinergic signaling pathways in the pathogenesis of human GVHD.
• To identify potential therapeutic targets and biomarkers for GVHD management.

Main Methods:

• Analysis of purinergic receptor activity (P2X7, A2A) in immune cells involved in GVHD.
• Investigating the impact of ATP and adenosine signaling on immune cell function and GVHD progression.

Main Results:

• P2X7 receptor activation on host antigen-presenting cells promotes GVHD induction.
• P2X7 receptor activation on regulatory T cells and other immune cells contributes to GVHD progression.
• Adenosine A2A receptor activation on donor T cells restricts GVHD development.

Conclusions:

• Purinergic signaling, particularly involving P2X7 and A2A receptors, plays a significant role in human GVHD.
• These purinergic signaling molecules represent promising therapeutic targets and biomarkers for GVHD.